How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,978 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. Full Text available with Trip Pro

Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. Killer-cell Immunoglobulin-like Receptors (KIR) interact with Human Leukocyte Antigen (HLA) to modify natural killer- and T-cell function. KIR are implicated in HIV acquisition by small studies that have not been widely replicated. A role for KIR in HIV disease progression is more widely replicated and supported by functional studies.To assess the role of KIR (...) and KIR ligands in HIV acquisition and disease course, we studied at-risk women in South Africa between 2004-2010. Logistic regression was used for nested case-control analysis of 154 women who acquired vs. 155 who did not acquire HIV, despite high exposure. Linear mixed-effects models were used for cohort analysis of 139 women followed prospectively for a median of 54 months (IQR 31-69) until 2014.Neither KIR repertoires nor HLA alleles were associated with HIV acquisition. However, KIR haplotype BB

2016 BMC Infectious Diseases

122. HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. Full Text available with Trip Pro

HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. South Africa has the highest number of people living with HIV in the world (over 6 million) as well as a rapidly aging population, with 15% of the population aged 50 and over. High HIV prevalence in rural former apartheid homeland areas suggests substantial aging with HIV and acquisition of HIV at older ages. We develop a life course approach to HIV vulnerability, highlighting (...) the rise and fall of risk and protection as people age, as well as the role of contextual density in shaping HIV vulnerability. Using this approach, we draw on an innovative multi-method data set collected within the Agincourt Health and Demographic Surveillance System in South Africa, combining survey data with 60 nested life history interviews and 9 community focus group interviews. We examine HIV risk and protective factors among adults aged 40-80, as well as how and why these factors vary among

2015 Social Science & Medicine

123. Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. Full Text available with Trip Pro

Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. Delayed tuberculosis (TB) diagnosis and treatment increase morbidity, mortality, expenditure, and transmission in the community. This study assessed patient and provider related delays to diagnosis and treatment of TB.A cross-sectional study was conducted among 735 new adult TB cases registered between January to December 2015 (...) predictors of delays and statistical significance was judged at p < 0.05.The median (inter-quartile range) of patient, provider and total delays were 25 (IQR;15-36), 22 (IQR:9-48) and 55 (IQR:32-100) days, respectively. More than half (54.6%) of the total delay was attributed to health system. Prior self-treatment [adjusted Odds Ratio (aOR)]: 1.72, 95% confidence interval [CI]:1.07-2.75), HIV co-infection (aOR:1.8, 95% CI: 1.05-3.10) and extra-pulmonary TB (aOR: 1.54,95% CI:1.03-2.29) were independently

2019 BMC Infectious Diseases

124. Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. Full Text available with Trip Pro

Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings. A nine-month course of daily isoniazid (INH) has been the longest prescribed therapy; however, completion rates are suboptimal. We need data to guide TB program outreach efforts (...) , 0.81), patients with diabetes (HR = 0.77, 95% CI: 0.60, 0.98), and patients with HIV (HR = 0.39, 95% CI: 0.30, 0.51) had a lower risk of treatment default. However, black patients (HR = 1.57, 95% CI: 1.44, 1.70), Hispanic patients (HR = 1.54, 95% CI: 1.43, 1.66), and non-U.S.-born persons living in the United States ≤5 years (HR = 1.25, 95% CI: 1.18, 1.32) were significantly more likely to default on therapy.In this analysis of INH treatment outcome, we see high levels of treatment discontinuation

2019 BMC Public Health

125. Therapeutic guidelines for antiretroviral (ARV) treatment of adult HIV infection

of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365:1482-1491. 33. Meintjes G, Wilkinson R, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome. AIDS 2010; 24:2381-2390. 34. Torok ME, Nguyen TB, Tran THC, et al Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374. 35. Hughes JP (...) diagnosis and when the patient is ready to start the therapy (C-III). There is no CD4 cell count threshold above which starting therapy is contraindicated and no demonstrated harm of early ART initiation. Ongoing observational cohorts continue to accumulate data confirming that the benefits of HIV treatment are maximized when it is started earlier in the course of the disease: • A combined analysis of 6699 ART-treated individuals in the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency

2020 CPG Infobase

126. Guidance for the use of post-exposure prophylaxis (PEP) for the prevention of HIV in British Columbia

care providers caring for persons who have experienced significant exposure to blood and/or body fluids in the work place or community setting. The risk of Human Immunodeficiency Virus (HIV) acquisition from a given exposure depends on the likelihood the source has transmissible HIV infection, and the biological risk of HIV transmission based on the exposure that has occurred. This guideline is designed to deal specifically with exposures to HIV and is not applicable to other exposures (...) -arv-guidelines/0 Toronto General Hospital, University Health Network Immunodeficiency Clinic. HIV/HCV Drug Therapy Guide. http://app.hivclinic.ca/ 19 XI REFERENCES 1. Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol 2013; 34: 875-92 2. Centers for Disease

2020 CPG Infobase

127. A Prospective Time Course Study on Serological Testing for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus with Blood Samples Taken up to 48 Hours After Death. Full Text available with Trip Pro

A Prospective Time Course Study on Serological Testing for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus with Blood Samples Taken up to 48 Hours After Death. The transmission of viral and non-viral infectious pathogens continues to be the most serious of the potential adverse effects of allogenic tissue transplantations. EU Directive 2006/17/EC stipulates that cadaveric blood specimens for serology testing in the context of post-mortem tissue donation must be taken (...) not later than 24 h post-mortem. An expanded time slot would significantly improve the availability of tissue donations, but there are no significant data on the stability of infectious serology assays for anti-human immunodeficiency virus (HIV), anti-hepatitis C virus (HCV), hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HBC core antigen (HBc) in samples collected more than 24 h post-mortem. In this prospective study, serum samples of 30 deceased persons were taken upon admission

2011 Journal of Medical Microbiology

128. Women?s health in NSW ? a life course approach

and obesity exacerbate the features of this condition 49 • Increased uptake of cervical screening is argued to be the best health behaviour to prevent against cervical cancer 50 alongside the Human Papilloma Virus vaccination program for adolescent women 51 • Over half (55.1%) of young women in NSW take up biennial cervical cancer screening. This rate has remained steady since 2003 52 • Women who are obese, reliant on welfare, current smokers, report childhood sexual abuse, and experience anxiety symptoms (...) Women?s health in NSW ? a life course approach Women’s health in NSW – a life course approach: a rapid review A Steel J Frawley A Dobson C Jackson J Lucke L Tooth W Brown J Byle G Mishra An Evidence Check review brokered by the Sax Institute for the NSW Ministry of Health March 2013 This report was prepared by: Amie Steel, Jane Frawley, Annette Dobson, Caroline Jackson, Jayne Lucke, Leigh Tooth, Wendy Brown, Julie Byles and Gita Mishra Centre for Research Excellence in Women’s Health in the 21

2013 Sax Institute Evidence Check

129. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

Assessment, Development and Evaluation HPV Human papilloma virus ICER Incremental cost-effectiveness ratio ICO Istituto Catala' d'Oncologia (Spain) LY Life years 9vHPV Nine-valent HPV vaccine PeIN Penile intraepithelial neoplasia PICO Population Intervention Comparison Outcome POTS Postural orthostatic tachycardia syndrome QALY Quality-adjusted life years 6MPI Six-month persistent infection VaIN Vaginal intraepithelial neoplasia VLP Virus-like particle VIN Vulvar intraepithelial neoplasia Glossary Cost (...) the most favorable conditions, e.g. experimental setting. Vaccine hesitancy Delay in acceptance or refusal of vaccines despite availability of vaccination services. Viroprevalence Prevalence of virus in population. SCIENTIFIC ADVICE Guidance on HPV vaccination in EU countries: focus on boys, PLHIV and 9-valent HPV vaccine introduction 1 Executive summary Scope This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas: efficacy/effectiveness of the 9-valent HPV

2020 European Centre for Disease Prevention and Control - Technical Guidance

130. Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Full Text available with Trip Pro

Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Financial education for HIV‐vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence - Lee - 2020 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Financial education for HIV (...) of Use. Shareable Link Use the link below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on 1 Children and youth are defined as those between 0 and 24 years by UN and UNICEF definitions ( , , retrieved on November 15, 2017). HIV is the leading cause of youth mortality in Africa, and the second cause of death among young people worldwide (UNAIDS, ; WHO, ). Young girls are particularly vulnerable (Fleischman & Peck, ), accounting for 20

2020 Campbell Collaboration

131. Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

immunosuppressive treatment are eligible. Vaccination within 4 weeks of the first dose of COMPOUND 2055269 and while on trials is prohibited except for administration of inactivated vaccines. Active infection requiring systemic therapy. Known history of testing positive for the human immunodeficiency virus or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive (...) Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

132. Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

ulcers or duodenal ulcers for the treatment of resistance; 3 or 4 grade gastrointestinal bleeding / bleeding; Gastrointestinal perforation / fistula; Abdominal abscess; Infectious or inflammatory bowel disease HIV infection and/or active hepatitis B virus infection Pregnant or lactating women. Fertile patients must use effective contraception Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study Other intervention (...) Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

133. Rifaximin to Modify the Disease Course in Sickle Cell Disease

receive any blood products within three weeks of the screening visit. Patients with uncontrolled liver disease or renal insufficiency, colitis, or inflammatory bowel disease. Patients with HIV, or other concomitant immunodeficiency. Patients on penicillin prophylaxis or antibiotics for treatment of infection. Patients with significant medical condition that require hospitalization (other than sickle cell VOC) within two months of the screening visit. Patients currently taking or has been treated (...) Rifaximin to Modify the Disease Course in Sickle Cell Disease Rifaximin to Modify the Disease Course in Sickle Cell Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rifaximin to Modify the Disease

2018 Clinical Trials

134. Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study. Full Text available with Trip Pro

Delays to treatment initiation is associated with tuberculosis treatment outcomes among patients on directly observed treatment short course in Southwest Ethiopia: a follow-up study. Despite reported long delays to initiate anti-TB treatment and poor outcomes in different parts of Ethiopia and elsewhere, evidences on association between the delay and treatment outcomes are scanty.A follow up study among 735 new TB cases registered at health facilities in districts of southwest Ethiopia (...) (ARR) = 1.92, 95%CI:1.30, 2.81], HIV co-infection (ARR = 2.18, 95%CI:1.47, 3.25) and received treatment at hospital (ARR = 3.73, 95%CI:2.23, 6.25). On the other hand, lower risk of unsuccessful outcome was predicted by weight gain (ARR = 0.40, 95%CI:0.19, 0.83) and sputum smear negative conversion (ARR = 0.17,95% CI:0.09, 0.33) at the end of second month treatment.Higher risk of unsuccessful outcome is associated with prolonged days elapsed between onset of illness and treatment commencement. Hence

2018 BMC Pulmonary Medicine

135. The Clinical Course of Patients with PSA≥100 Ng/mL: Insight Into a Potential Population for Targeted PSA Screening. (Abstract)

was 8. Median age at presentation was 67.4 years (minimum, 40.8 and maximum, 90.6). Eighty-nine percent of patients were African American, 24% lived alone, 12% were homeless or incarcerated, 51% were insured by Medicare or Medicaid, and 47% were uninsured. Only 1% had human immunodeficiency virus, 19% had diabetes, and 13% had chronic kidney disease. Of the 65 newly diagnosed patients, only 23% had ever been screened and 9% were previously biopsied. Median time from presentation to death was 17.8 (...) The Clinical Course of Patients with PSA≥100 Ng/mL: Insight Into a Potential Population for Targeted PSA Screening. To characterize men presenting to a tertiary care safety-net hospital with prostate-specific antigen (PSA) values ≥100 ng/mL and to identify a potential population for targeted PSA screening.Retrospective review of 100 randomly selected patients of a total of 204 who presented to Grady Memorial Hospital from 2004 to 2011 with initial PSA ≥100 ng/mL was performed. Demographics

2018 Urology

136. Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease

Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease (FLM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03748511 Recruitment Status : Not yet recruiting

2018 Clinical Trials

137. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years Full Text available with Trip Pro

Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years Despite modern intensive care with standardized strategies against acute respiratory distress syndrome (ARDS), Pneumocystis pneumonia (PcP) remains a life-threatening disease with a high mortality rate. Here, we analyzed a large mixed cohort of immunocompromised patients with PcP, with regard to clinical course and treatment, and aimed at identifying predictors (...) of outcome.This was a single-center retrospective analysis in a tertiary care institution across 17 years. Diagnosis of PcP required typical clinical features and microbiological confirmation of Pneumocystis jirovecii. Epidemiological, clinical, laboratory and outcome data were collected from patient records.A total of 52,364 specimens from 7504 patients were sent for microbiological assessment (3653 with clinical suspicion of Pneumocystis pneumonia). PcP was confirmed in 240 patients, about half of them HIV

2018 Critical Care

138. Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V

DTG dolutegravir EFV efavirenz FTC emtricitabine G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIV-1 human immunodeficiency virus type 1 IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) NNRTI non-nucleoside reverse transcriptase inhibitor NRTI nucleoside/nucleotide reverse transcriptase inhibitor RCT randomized controlled trial RNA ribonucleic acid SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product (...) doravirine (DOR). The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as the “company”). The dossier was sent to IQWiG on 14 January 2019. Research question The aim of this report is to assess the added benefit of DOR in combination with other antiretroviral drugs in comparison with the appropriate comparator therapy (ACT) in adults infected with human immunodeficiency virus type 1 (HIV-1). The HI viruses must not have mutations known to be associated

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

139. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. Full Text available with Trip Pro

First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. The aim of the study was to investigate the impact of first-line combined antiretroviral therapy (cART) regimen on the course of CD8 T-cell counts in human immunodeficiency virus (HIV)-infected patients.A retrospective observational study conducted on the French DAT'AIDS Cohort of HIV-infected patients.We selected 605 patients initiating a first-line cART (...) between 2002 and 2009, and which achieved a sustained undetectable HIV plasma viral load (pVL) for at least 12 months without cART modification. The evolution of CD8 T-cell counts according to cART regimen was assessed.CD8 T-cell counts were assessed in 572 patients treated with 2NRTIs+1PI/r (n= 297), 2NRTIs+1NNRTI (n= 207) and 3NRTIs (n= 68). In multivariate analysis, after 12 months of follow-up, the 3NRTIs regimen was associated with a significantly smaller decrease of CD8 T-cell count compared

2016 Medicine

140. Accelerated CD4 decline in untreated HIV-1 patients points toward increasing virulence over the course of the epidemic. (Abstract)

Accelerated CD4 decline in untreated HIV-1 patients points toward increasing virulence over the course of the epidemic. Based on the assumption that the rate of CD4 cell count loss in treatment-naïve patients is correlated with the virulence of HIV-1, we evaluated 4616 patients. Patients who entered a German national database between 1985 and 1995 had a median annual CD4 cell count loss of 48 cells/μl, whereas those registered between 1999 and 2009 had a median annual CD4 cell count loss of 68 (...) cells/μl (P < 0.001). This suggests that HIV-1 virulence has increased over the course of the epidemic.

2016 AIDS

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>